A Targeted Next-Generation Sequencing Panel to Genotype Gliomas

Area of Science:

• Neuro-oncology
• Molecular Diagnostics
• Genomics

Background:

• Gliomas represent the most common primary brain tumors, with glioblastoma being the most malignant subtype.
• Tumorigenesis and treatment response in gliomas are influenced by molecular heterogeneity.
• Accurate molecular classification is crucial for glioma diagnosis, prognosis, and therapy.

Purpose of the Study:

• To develop and validate a targeted next-generation sequencing (NGS) approach for analyzing glioma molecular alterations.
• To assess the utility of NGS in identifying variants and chromosomal aberrations linked to glioma development and treatment resistance.
• To provide a comprehensive molecular profile of gliomas within a single workflow.

Main Methods:

• Development and validation of a targeted NGS panel.
• Analysis of 13 glioma-related genes, the TERT promoter region, and 54 SNPs on chromosomes 1 and 19.
• Assessment of variants, chromosomal aberrations, and copy number alterations (CNAs).

Main Results:

• The targeted NGS approach demonstrated high accuracy, specificity, and sensitivity in profiling glioma molecular heterogeneity.
• The method successfully detected variants associated with poor outcomes, disease progression, and drug resistance.
• A comprehensive molecular portrait of gliomas was achieved in a single workflow.

Conclusions:

• The developed targeted NGS approach is effective for characterizing glioma molecular landscape.
• This method facilitates the identification of key molecular markers for glioma classification and patient stratification.
• Preliminary findings support the integration of this NGS approach into routine diagnostic neuropathology for improved glioma management.